Alpha 2.0
Login Register
» Articles » PMID: 7261254

Doxorubicin Pharmacokinetics After Intravenous and Intraperitoneal Administration in the Nude Mouse

Overview
Journal Cancer Chemother Pharmacol
Specialty Oncology
Date 1981 Jan 1
PMID 7261254
Citations 36
Authors
P B Johansen
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of doxorubicin in nude mice have been investigated following intravenous and intraperitoneal administration of single doses of 12 mg/kg. The areas under the concentration curves of doxorubicin in kidney, heart, and striated muscle following intraperitoneal administration were approximately half the areas following intravenous injection, whereas plasma and liver showed nearly identical concentrations after a distribution phase of 2 h. Only minor differences in pharmacokinetics were found between nude and normal mice.

Citing Articles

Comprehensive transthoracic echocardiographic evaluation of doxorubicin-induced cardiotoxicity: a multimodal imaging approach in an animal model.

Haesen S, Steegen L, Deluyker D, Bito V Eur Heart J Imaging Methods Pract. 2025; 3(1):qyaf006.

PMID: 39974275 PMC: 11837189. DOI: 10.1093/ehjimp/qyaf006.

PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration-time profile of encapsulated and free doxorubicin in tissues.

Cao X, Li K, Wang J, Xie X, Sun L Drug Deliv Transl Res. 2024; 15(4):1342-1362.

PMID: 39103592 DOI: 10.1007/s13346-024-01680-0.

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.

Yalamarty S, Filipczak N, Pathrikar T, Cotter C, Ataide J, Luther E Drug Deliv Transl Res. 2024; 14(8):2171-2185.

PMID: 38507033 PMC: 11208241. DOI: 10.1007/s13346-024-01562-5.

The Distant Molecular Effects on the Brain by Cancer Treatment.

Demos-Davies K, Lawrence J, Ferreira C, Seelig D Brain Sci. 2024; 14(1).

PMID: 38248237 PMC: 10813787. DOI: 10.3390/brainsci14010022.

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.

Yalamarty S, Filipczak N, Pathrikar T, Cotter C, Ataide J, Luther E Res Sq. 2024; .

PMID: 38168301 PMC: 10760232. DOI: 10.21203/rs.3.rs-3713164/v1.

References
1.
Martini A, Donelli N, Mantovani A, Pacciarini M, Morasca L, Garattini S . Antineoplastic activity and pharmacokinetics of adriamycin and daunomycin in tumor bearing mice. Oncology. 1977; 34(4):173-8. DOI: 10.1159/000225216. View
2.
Di Fronzo G, Gambetta R, Lenaz L . Distribution and metabolism of adriamycin in mice. Comparison with daunomycin. Rev Eur Etud Clin Biol. 1971; 16(6):572-6. View
3.
Ozols R, Locker G, Doroshow J, Grotzinger K, Myers C, Young R . Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979; 39(8):3209-14. View
4.
Arena E, DAlessandro N, Dusonchet L, Gebbia N, GERBASI F, PALAZZOADRIANO M . Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneimittelforschung. 1971; 21(8):1258-63. View
5.
Lenaz L, Di Marco A . On the reported lack of effectiveness of daunomycin (NSC-82151) and adriamycin (NSC-123127) on solid tumors. Cancer Chemother Rep. 1972; 56(4):431-2. View